Abbott offers EU concessions over $25 billion St Jude deal
Reuters
Published Nov 03, 2016 16:47
Abbott offers EU concessions over $25 billion St Jude deal
BRUSSELS (Reuters) - Medical device maker Abbott Laboratories (N:ABT) has offered concessions in an attempt to secure EU antitrust approval for its $25 billion (£21 billion) bid for St Jude Medical Inc (N:STJ), according to the European Commision.
The move pushed back the European Commission's decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer's website on Thursday. It did not provide details.
The Commission can either accept the offer, demand more or open an investigation which can take up to five months.
Abbott and St Jude last month announced the sale of some of their medical devices worth about $1.12 billion to Japanese company Terumo Corp (T:4543) as part of their deal.
The deal comes as medical equipment makers come under pressure to offer a wider range of products to hospital customers.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.